吉西他滨联合奈达铂与紫杉醇治疗顺铂耐药的转移性鼻咽癌  

Treatment of gemcitabine combined with nedaplatin and paclitaxel for patients with metastatic cisplatin-resistant nasopharyngeal carcinoma

作　　者：潘燚[1] 李伟雄[1] 谢松喜[1] 林映如[1] 张红丹[1] 

机构地区：[1]广东省人民医院肿瘤中心放疗科,广州510080

出　　处：《肿瘤研究与临床》2010年第8期519-520,共2页Cancer Research and Clinic

摘　　要：目的 观察吉西他滨联合奈达铂与紫杉醇治疗对顺铂耐药的转移性鼻咽癌的近期疗效及不良反应.方法 15例顺铂方案化疗失败的转移性鼻咽癌患者.吉西他滨1000 mg/m2,第1、8天;奈达铂70mg/m2,第1天;紫杉醇135 mg/m2,第1天;21 d为1个疗程,疗效评价采用RECIST 3.0标准.结果 全组15例患者CR 1例,PR 5例,SD 6例,PD 3例,总有效（CR＋PR）率40.0%.中位TTP为4.7个月,中位生存期为6.3个月.主要不良反应为血液学毒性,Ⅲ＋Ⅳ度骨髓抑制的发生率分别为：白细胞减少40.0%、贫血6.7%、血小板减少20.0%.其他不良反应轻微.结论 吉西他滨联合奈达铂与紫杉醇的化疗方案可作为顺铂耐药转移性鼻咽癌的二线方案.Objective To assess the short-term effects and adverse reactions of combination regimen of gemcitabine, nedaplatin and paclitaxel for patients with metastatic cisplatin-resistant nasopharyngeal carcinoma （NPC）. Methods A total of 15 patients with metastatic cisplatin-resistant NPC were enrolled. All patients were treated with a combination regimen including gemcitabine with 1000 mg/m2 on day 1st and 8th, nedaplatin with 70 mg/m2 on day 1st and paclitaxel with 135 mg/m2 on day 1st, repeated every 21 days. Response was evaluated according to Response Evaluation Criteria in Solid Tumors （RECIST） criteria 3.0. Results The overall response rate was 40.0 %, with a complete response rate of 6.7 % （1/15） and a partial response rate of 33.3 % （5/15）. Six patients （40.0 %） had stable disease and 3 patients （20.0 %） had progressive disease. The median time to progression （TTP） was 4.7 months and the median overall survival was 6.3 months. Hematological toxicities were the adverse reaction with 40.0 % of leucopenia, 6.7 % of anemia and 20.0 % thrombocytopenia. One patient needed for platelet transfusion. Other adverse reactions were mild. Conclusion The combination regimen of gemcitabine, nedaplatin and paclitaxel is feasible as second-line chemotherapy in patients with metastatic cisplatin-resistant NPC.

关 键 词：鼻咽肿瘤 药物疗法 联合 

分 类 号：R739.63[医药卫生—肿瘤]